Search

everythinglearnresearchcommunity

for

Search:↓

The microneedle patches effectively treat allergic conjunctivitis with controlled, sustained release of medication.

TAK-279 effectively reduces psoriasis symptoms and is safe.

OR101 may effectively treat atopic dermatitis and similar skin conditions.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

Majocchi's granuloma can occur in kidney transplant patients on tacrolimus and can be treated with antifungal medication.

Astilbin can potentially calm overactive immune responses, like in Type 1 Diabetes, by suppressing certain cell activities and reducing inflammation.

IL-3 worsens lupus nephritis and blocking it improves kidney health.

Tislelizumab can cause cutaneous lupus erythematosus.

Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.

Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.

Melatonin can improve treatment and extend remission for certain skin conditions.

Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.

Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.

Lulican™ shampoo is more effective and better tolerated than Ketoconazole for treating scalp seborrheic dermatitis.

Calcipotriol works almost as well as clobetasol for mild to moderate alopecia areata with fewer side effects.

Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.

Ustekinumab and vedolizumab can help some ulcerative colitis patients with hair regrowth, but results vary.

All four treatments for early rheumatoid arthritis had similar safety profiles.

Dupilumab effectively reduces alopecia areata symptoms in children with atopic dermatitis.

Betamethasone is more effective long-term for alopecia areata than hydroxychloroquine.

Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

Dupilumab helps children with alopecia areata regrow hair safely.

Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.

Olumiant should be covered for severe alopecia areata if certain conditions are met.

Etanercept effectively treated a severe skin condition when other treatments failed.

Younger patients and those with more hair loss are less likely to benefit from oral steroid treatment for hair loss, and low vitamin D may predict relapse.

Retinol palmitate may reduce cancer relapses in early-stage lung cancer patients.

Further trials are needed to explore the efficacy of triamcinolone acetonide in dermatology.